Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry.

ABSTRACT:

Background

Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. In clinical studies, dupilumab reduced the risk of severe asthma exacerbations, and improved forced expiratory volume in 1 s and quality of life in patients with uncontrolled moderate-to-severe asthma.

Objectives

The objectives of RAPID (NCT04287621) are to characterize patients with asthma initiating dupilumab in routine clinical practice and to collect information on long-term effectiveness and safety in these patients.

Methods

RAPID is a global, prospective, observational registry that will enroll approximately 1000 patients (aged ≥ 12 years) with asthma from 150 sites globally. Dupilumab

SUBMITTER: Gall R 

PROVIDER: S-EPMC9988992 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature